Skip to main content
. 2012 Aug 3;70(3):451–459. doi: 10.1007/s00280-012-1938-3

Table 2.

Efficacy of LD-GP and other regimens for measurable tumors

LD-GP therapy
(n = 35)
Others regimens
(n = 23)
P value
Complete response 0 (0.0) 1 (4.3) 0.220
Partial response 9 (25.7) 3 (13.0)
Stable disease 22 (62.9) 13 (56.5)
Progressive disease 4 (11.4) 6 (26.1)

LD-GP low-dose combined therapy of gemcitabine and paclitaxel